U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07746583) titled 'A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical Practice' on July 29.
Brief Summary: The main purpose of this study is to describe how well Guselkumab works after switching from Ustekinumab in participants with moderate to severe psoriasis in a routine clinical setting. A long-term skin disease that causes red, scaly and sometimes painful, itchy patches on the skin.
Study Start Date: Aug. 07
Study Type: OBSERVATIONAL
Condition:
Psoriasis
Recruitment Status: RECRUITING
Sponsor: Janssen-Cilag Kft.
Published by HT Digital Content Services with permission from Hea...